药明合联生物技术有限公司(02268，下称“药明合联”)与东曜药业-B(01875，下称“东曜药业”)13日联合公告，药明合联透过花旗环球金融亚洲有限公司按每股现金方式提出的自愿有条件全面收购及购股权注销要约，于首个截止日期（3月13日16:00）已接获359,633,024股有效接纳，占东曜药业已发行股本约46.54%。\n\n同时，购股权要约获接纳6,512,600份，约占东曜药业截至公告日尚未行使购股权总数的85.33%。由于股份要约需达到不少于60%投票权的接纳条件，目前该条件尚未满足，股份要约及购股权要约均未生效。\n\n药明合联已将要约期限由3月13日延长至3月27日16:00，其余条款维持不变。根据此前签署的不可撤销承诺，如要约人在首个截止日未满足接纳条件，以下股东须于3月17日15:00前就下列缺额承诺股份接纳要约：Advantech Capital Investment 9,458,156股、晟德大药厂47,290,777股及维梧苏州47,290,777股。\n\n按修订后的时间表，收购方将于3月27日当日或之前公布要约结果；若要约在该日成为无条件状态，相关对价的支票将最迟于4月10日寄发。要约一旦无条件，将至少再开放14日，最迟无条件日期为4月13日19:00。\n\n公告提醒股东、受限制股份奖励持有人、购股权持有人及潜在投资者，完成要约仍须满足或获豁免全部条件，投资者买卖东曜药业及药明合联证券时应审慎行事。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.